FibroBiologics, Inc. Common Stock (FBLG) 10-Year Financial Performance & Capital Metrics

FBLG • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutFibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.Show more

Revenue $0
EBITDA -$13M -55.8%
Net Income -$11M +32.3%
EPS (Diluted) -0.34 +42.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -559.73% +57.5%
ROIC -
Debt/Equity 3.86 +176.7%
Interest Coverage -686.85 -1035.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗High debt to equity ratio of 3.9x
✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 16 (bottom 16%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-4.06%

EPS CAGR

10Y-

5Y-

3Y-

TTM14.45%

ROCE

10Y Avg-1925.66%

5Y Avg-1925.66%

3Y Avg-1925.66%

Latest-432.19%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	0	0	0	0
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-
Operating Expenses+	1.17M	1.58M	4.47M	8.89M	13.74M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	500K	1.06M	3.32M	6.52M	9.23M
SG&A % of Revenue	-	-	-	-	-
Research & Development	669K	521K	1.15M	2.37M	4.5M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0
Operating Income+	-1.17M	-1.58M	-4.47M	-8.89M	-13.74M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-0.35%	-1.83%	-0.99%	-0.55%
EBITDA+	0	-1.58M	-4.37M	-8.45M	-13.16M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	-	-1.77%	-0.93%	-0.56%
D&A (Non-Cash Add-back)	1.17M	0	94K	437K	573K
EBIT	-1.17M	-1.58M	-4.47M	-16.34M	-11.14M
Net Interest Income+	0	-4K	-654K	-147K	231K
Interest Income	0	0	0	0	251K
Interest Expense	0	4K	654K	147K	20K
Other Income/Expense	0	-4K	-654K	-7.6M	2.58M
Pretax Income+	-1.17M	-1.58M	-5.12M	-16.48M	-11.16M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-1.17M	-1.58M	-5.12M	-16.48M	-11.16M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-0.35%	-2.24%	-2.22%	0.32%
Net Income (Continuing)	-1.17M	-1.58M	-5.12M	-16.48M	-11.16M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.04	-0.05	-0.16	-0.59	-0.34
EPS Growth %	-	-0.35%	-2.29%	-2.69%	0.42%
EPS (Basic)	-0.04	-0.05	-0.16	-0.59	-0.34
Diluted Shares Outstanding	32.49M	32.48M	32.48M	32.49M	32.88M
Basic Shares Outstanding	32.49M	32.48M	32.48M	32.49M	32.88M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	0	468K	2.63M	9.21M	14.23M
Cash & Short-Term Investments	0	407K	2.27M	9.16M	13.98M
Cash Only	0	407K	2.27M	9.16M	13.98M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	0	0	300K	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	24K	30K	16K	18K
Total Non-Current Assets+	0	0	2.2M	2.61M	2.22M
Property, Plant & Equipment	0	0	2.2M	2.61M	2.22M
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0
Total Assets+	0	468K	4.82M	11.82M	16.45M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	-	9.31%	1.45%	0.39%
Total Current Liabilities+	0	1.76M	7.07M	9.18M	12.73M
Accounts Payable	0	233K	493K	1.44M	2.7M
Days Payables Outstanding	-	-	-	-	-
Short-Term Debt	0	1.3M	5.45M	0	9.17M
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	0	0	803K	7.24M	460K
Current Ratio	-	0.27x	0.37x	1.00x	1.12x
Quick Ratio	-	0.27x	0.37x	1.00x	1.12x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	0	0	1.75M	1.39M	984K
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	0	0	1.75M	1.39M	984K
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0
Total Liabilities	0	1.76M	8.82M	10.57M	13.71M
Total Debt+	0	1.3M	7.52M	1.75M	10.55M
Net Debt	0	893K	5.26M	-7.42M	-3.43M
Debt / Equity	-	-	-	1.39x	3.86x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-394.50x	-6.83x	-60.47x	-686.85x
Total Equity+	0	-1.29M	-4M	1.25M	2.73M
Equity Growth %	-	-	-2.1%	1.31%	1.18%
Book Value per Share	-	-0.04	-0.12	0.04	0.08
Total Shareholders' Equity	0	-1.29M	-4M	1.25M	2.73M
Common Stock	1.17M	0	1K	1K	0
Retained Earnings	-1.17M	-2.75M	-7.87M	-24.36M	-35.52M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	1.46M	0	0
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.17M	-1.41M	-4.07M	-6.4M	-11.9M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-0.21%	-1.88%	-0.57%	-0.86%
Net Income	-1.17M	-1.58M	-5.12M	-16.48M	-11.16M
Depreciation & Amortization	0	0	94K	437K	573K
Stock-Based Compensation	0	0	265K	1.76M	2.22M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	0	0	389K	7.39M	-4.09M
Working Capital Changes	0	172K	307K	493K	559K
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	0	0	525K	671K	1.25M
Cash from Investing+	0	0	0	-495K	-184K
Capital Expenditures	0	0	0	-495K	-184K
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	1.17M	1.82M	5.92M	13.79M	16.91M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	1.17M	292K	0	-2.65M	0
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-1.17M	-1.41M	-4.07M	-6.9M	-12.09M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-0.21%	-1.88%	-0.7%	-0.75%
FCF per Share	-0.04	-0.04	-0.13	-0.21	-0.37
FCF Conversion (FCF/Net Income)	1.00x	0.89x	0.79x	0.39x	1.07x
Interest Paid	0	0	0	2K	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-1315.64%	-559.73%
Return on Invested Capital (ROIC)	-	-	-774.62%	-	-
Debt / Equity	-	-	-	1.39x	3.86x
Interest Coverage	-	-394.50x	-6.83x	-60.47x	-686.85x
FCF Conversion	1.00x	0.89x	0.79x	0.39x	1.07x

Frequently Asked Questions

Growth & Financials

FibroBiologics, Inc. Common Stock (FBLG) grew revenue by 0.0% over the past year. Growth has been modest.

FibroBiologics, Inc. Common Stock (FBLG) reported a net loss of $18.5M for fiscal year 2024.

Dividend & Returns

FibroBiologics, Inc. Common Stock (FBLG) has a return on equity (ROE) of -559.7%. Negative ROE indicates the company is unprofitable.

FibroBiologics, Inc. Common Stock (FBLG) had negative free cash flow of $16.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener